OncoMed Announces Abstracts Accepted for Presentation at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed Announces Abstracts Accepted for Presentation at the 2015 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq: OMED ) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology candidates at the upcoming American Society of Clinical Oncology (ASCO) 2015 Annual Meeting.

OncoMed will present new clinical data from clinical trials of its lead anti-cancer stem cell therapeutics, demcizumab and tarextumab. Final data from OncoMed's Phase 1b clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in small cell lung cancer will be presented by Dr. M. Catherine Pietanza, MD, of Memorial Sloan-Kettering Cancer Center during a poster discussion session. New data from the company's Phase 1b clinical trials of demcizumab (OMP-21M18, anti-DLL4) in pancreatic cancer and non-small cell lung cancer (NSCLC) will be presented in posters during the meeting. The list of abstracts and timing of the presentations is provided below.

Poster Discussion
   
Monday, June 1, 2015 from 1:15 pm – 2:30 pm
Abstract #7508:  Final results of phase 1b of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Lead author:  Dr. M. Catherine Pietanza, MD, of Memorial Sloan-Kettering Cancer Center
Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Location: E hall D2
   
Poster Display Information: Monday, June 1, 2015 from 8:00 am – 11:30 am
Location: S Hall A
   
Posters  
   
Monday, June 1, 2015 from 8:00 am – 11:30am
Abstract #4118:  A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.
Lead author: Manuel Hidalgo, MD, PhD, Director of the Centro Integral Oncológico Clara Campal (CIOCC), START Madrid
Session: Gastrointestinal (Noncolorectal) Cancer
Location: S Hall A
   
Monday, June 1, 2015 from 8:00 am – 11:30am
Abstract #8045:  A Phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients with 1st line non-squamous NSCLC.
Lead author: Dusan Kotasek MBBS, FRACP, Adelaide Cancer Centre
Session: Lung Cancer—Non-Small Cell Metastatic
Location: S Hall A

About Cancer Stem Cells

Cancer stem cells, or CSCs, are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor.  CSCs, also known as tumor-initiating cells, exhibit certain properties which include the capacity to divide and give rise to new CSCs via a process called self-renewal and the capacity to differentiate or change into the other cells that form the bulk of the tumor.  Common cancer drugs target bulk tumor cells but have limited impact on CSCs, thereby providing a path for recurrence of the tumor. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells.  OncoMed believes its product candidates are distinct from the current generations of chemotherapies and targeted therapies, and have the potential to significantly impact cancer treatment and the clinical outcome of patients with cancer.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed recently filed an Investigational New Drug application for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com .

Media & Investors OncoMed Pharmaceuticals Michelle Corral Senior Director, Investor Relations and Corporate Communications (650) 995-8373 Investors Shari Annes Annes Associates (650) 888-0902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 244

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 385

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 234

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 430

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading

Top 5 Most Recently Viewed Articles

HUB Cyber Security's Roadmap for Revolutionary Financial Solutions

Updated Category News Views 164

HUB Cyber Security Unveils Revolutionary Financial Solutions HUB Cyber Security Ltd. (Nasdaq: HUBC) has shared an ambitious roadmap to launch the HUB Token (HUBT), positioning itself as a pioneer in the rapidly evolving digital finance landscape. This strategic initiative aims to power the innovative Trvsthub™ platform, which promises to enhance the security and...

Continue Reading
MSU Energy Completes Successful Exchange Offer for Senior Notes

Updated Category News Views 227

MSU Energy Completes Successful Exchange of Senior Notes MSU Energy S.A. has announced the results of its recent exchange offer, which culminated successfully within an established timeframe. This initiative involved an exchange for up to $218,973,000 in aggregate principal amount of its existing 6.875% Senior Notes due 2025. The transition to new financial instruments...

Continue Reading
Major Defense Contracts Awarded to Lockheed and Boeing

Updated Category News Views 304

The Pentagon's New Contracts The recent contracts awarded by the Pentagon to Lockheed Martin Corporation (NYSE: LMT) and Boeing Company (NYSE: BA) exemplify the ongoing investment in national defense. These new agreements underscore a robust financial commitment to enhancing military capabilities. Lockheed Martin's Taiwan FMS Award Lockheed Martin has secured a pivotal...

Continue Reading
Maryland Army National Guard's General Birckhead to Address Graduates

Updated Category News Views 134

General Janeen L. Birckhead to Inspire Graduates at HCC Columbia, MD — A significant moment is approaching for over 1,100 graduates of Howard Community College (HCC) as they prepare to celebrate their accomplishments at the upcoming commencement exercises. The keynote speaker for this year's ceremony is none other than Major General Janeen L. Birckhead, Adjutant General...

Continue Reading
SUNation Energy Announces Participation in Annual Roth Conference

Updated Category News Views 133

SUNation Energy to Engage in Investment Discussions SUNation Energy, Inc. (Nasdaq: SUNE), a prominent provider of solar energy and power solutions, has made it's presence known as it prepares to take part in a significant investor conference. The upcoming event, known as the Annual Roth Conference, serves as a pivotal platform where growth companies showcase their...

Continue Reading